Pfizer's Xalkori gets a lung cancer indication in EU and Lilly's Portrazza gets one from FDA; Pfizer's Lyrica comes up short in post-traumatic neuropathic pain trial;

@FiercePharma: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Pfizer ($PFE) has won a label expansion in the EU for Xalkori as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Release

> Pfizer's blockbuster pain drug, Lyrica failed to show benefit in patients suffering from a type of post-traumatic neuropathic pain, for which there is no approved drug in the U.S. Story

> Daiichi Sankyo is teaming up with Sanofi's ($SNY) Japanese unit to launch Squarekids, a DPT-polio vaccine, in Japan. Story

> The FDA has approved Eli Lilly's ($LLY) Portrazza to treat advanced squamous non-small cell lung cancer. Release

> Mylan has launched Clozapine orally disintegrating tablets--a generic of Jazz Pharmaceutical's ($JAZZ) FazaClo--in the U.S. Release

Medical Device News

@FierceMedDev: Cigna rolls out new coverage policy for whole exome sequencing. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @EmilyWFierce

> Entellus wins FDA clearance for its endoscope to treat blocked sinus passages. More

> Alphabet gives startups a lesson in financial management. Article

Biotech News

@FierceBiotech: FierceBiotech Radio on the ins and outs of 'Pfizergan' and whatever it is Martin Shkreli's doing. More | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

> Novo Nordisk taps Ablynx in a $400M deal. Item

> Allergan scoops up some CNS drugs as its $160B Pfizer merger pends. More

Pharma Marketing News

> Meda breaks down asthma with Medikidz comic book series for children. Report

> Kantar Media survey: Not all docs hate all ads. Article

> Turing sidesteps list-price discount on jacked-up therapy Daraprim. Item

> Purple haze: Dr. Reddy's strikes back at AstraZeneca in Nexium court battle. Story

> If TV's everywhere, then where does pharma need to be? More

Biotech Research News

> Sanford Burnham team sees promise in new melanoma drug. More

> Fruit flies may provide a biomarker for early-onset Parkinson's. Item

> U.K. investigators publish small, promising study of Victoza for NASH. Report

> Arno's HDAC inhibitor looks promising in preclinical cachexia study as cash runs low. Story

> Mount Sinai team maps a key combo role for new checkpoint drugs. Article

Vaccines News

> Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan. News

> Vaxart's oral RSV candidate protects in preclinical challenge. Report

> SUNY Upstate Medical University, U.S. Army start $12M partnership toward dengue vaccine. More

> FDA expands indication of Emergent BioSolutions anthrax vaccine. Article

> Celldex's brain cancer vaccine Rintega shows survival advantage at 2-year mark. Story

And Finally... The FDA has expanded the indication of Emergent BioSolutions ($EBS) anthrax vaccine, BioThrax, for use in adults aged 18 to 65 in conjunction with antibiotic treatment, following confirmed or suspected exposure. Story

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.